APA (7th ed.) Citation

Sackeyfio, A., Gill, J., Hettle, R., Siddiqui, K., Friedlander, M., & Ledermann, J. (2017). PCN5 - Comparative Efficacy And Safety of Olaparib 400 Mg Capsules Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients with Platinum-Sensitive Relapsed Non-Germline BRCA-Mutated Ovarian Cancer (PSROC). Value in Health, 20(9), A412. https://doi.org/10.1016/j.jval.2017.08.087

Chicago Style (17th ed.) Citation

Sackeyfio, A., J. Gill, R. Hettle, K. Siddiqui, M. Friedlander, and JA Ledermann. "PCN5 - Comparative Efficacy And Safety of Olaparib 400 Mg Capsules Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients with Platinum-Sensitive Relapsed Non-Germline BRCA-Mutated Ovarian Cancer (PSROC)." Value in Health 20, no. 9 (2017): A412. https://doi.org/10.1016/j.jval.2017.08.087.

MLA (9th ed.) Citation

Sackeyfio, A., et al. "PCN5 - Comparative Efficacy And Safety of Olaparib 400 Mg Capsules Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients with Platinum-Sensitive Relapsed Non-Germline BRCA-Mutated Ovarian Cancer (PSROC)." Value in Health, vol. 20, no. 9, 2017, p. A412, https://doi.org/10.1016/j.jval.2017.08.087.